Who We Are
The company was founded in 2012 after a cold-call pitch to the Pentagon with a new concept for a Brain-Computer Interface by Thomas Oxley. Seed funding was provided by DARPA, ONR Global and the National Health and Medical Research Council of Australia. The company (formerly known as SmartStent) spun out of the University of Melbourne, and continues to have close ties to the Vascular Bionics Laboratory in the Department of Medicine (Royal Melbourne Hospital). Series A funding was led by NeuroTechnology Investors, with veteran neurovascular entrepreneur Martin Dieck joining the board of directors as Chairman. The company has its corporate headquarters in Silicon Valley, in Campbell, California.
Stentrode™ and DARPA
Deep Roots in DARPA
Over the last 50 years, The U.S. Defense Advanced Research Projects Agency (DARPA) has funded critical scientific research that has led to development of signficant advances: the internet, mobile phones, GPS, robots, and artificial intelligence.
More recently, the focus has turned to neuroscience. After reaching apparent limitations on our ability to overcome the problem of neurological trauma and injury, the question has become: where to next? DARPA has been visionary in approaching these problems, and has provided large scale funding for cutting edge research to scientists willing to think outside the box.
Synchron has at its core a visionary and radical approach to problem-solving.